InvestorsHub Logo
Followers 9
Posts 66
Boards Moderated 0
Alias Born 01/30/2018

Re: None

Wednesday, 06/29/2022 3:17:09 PM

Wednesday, June 29, 2022 3:17:09 PM

Post# of 403234
Quick Lannett ER Update

Good afternoon everyone, so I went through the orange book for Lannett's approvals and the good news is that it appears they have parked by discontinuing their recently approved Adderall ER for now, this could be to keep their ANDA numbers low so they do not have to pay for a higher facility fee based on active ANDAs. But the good news is that so far they are only selling Elite's ER drug so hopefully that will give us a full year of sales in Walgreens, potentially 5-8% market share if the same as the IR product as we currently are getting 25-28M/Year in the IR market. Keep in mind Discontinued does not mean withdrawn so once they start selling their ANDA then the status will change, this however lets us know that Elite's drug is still active. Cheers and hope for a great Earning report tonight.

Active Ingredient: AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE
Proprietary Name: DETROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE
Dosage Form; Route of Administration: CAPSULE, EXTENDED RELEASE; ORAL
Strength: 1.25MG;1.25MG;1.25MG;1.25MG
Reference Listed Drug: No
Reference Standard: No
TE Code:
Application Number: A214403
Product Number: 001
Approval Date: Nov 26, 2021
Applicant Holder Full Name: LANNETT CO INC
Marketing Status: Discontinued
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ELTP News